LUTATHERA 370 MBq (Lutetium (177lu) Oxodotreotide SOLUTION) 370 MBq

LUTATHERA 370 MBq is a specialized intravenous solution containing Lutetium (177Lu) Oxodotreotide. This medication is designed for targeted therapeutic use in specific medical conditions. Learn more about its applications and effects.

Strength

370 MBq

Manufacturer / TM Owner

NOVARTIS PHARMACEUTICALS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

LUTATHERA 370 MBq is primarily used in the treatment of certain types of cancer that express somatostatin receptors. This medication works by delivering targeted radiation to these receptors, which can help in managing the growth of cancer cells. Patients often wonder, 'What is LUTATHERA used for?' and the answer lies in its ability to provide a precise and targeted approach to cancer therapy.

Side Effects

Common effects of LUTATHERA 370 MBq may include fatigue, nausea, and vomiting. Some patients might experience a temporary decrease in blood cell counts. These effects are generally monitored by healthcare professionals to ensure patient safety and comfort during treatment.

Precautions & Warnings

LUTATHERA 370 MBq should be handled with care, as it contains radioactive material. It is important to follow the guidelines provided by healthcare professionals regarding its administration and storage. Patients should also be aware of the potential risks and discuss any concerns with their healthcare provider.

Avoid Interactions

LUTATHERA 370 MBq may interact with other medications, particularly those that affect kidney function or blood cell production. It is crucial to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements might also impact the effectiveness of this treatment.

Frequently Asked Questions

LUTATHERA 370 MBq is used in the treatment of certain types of cancer that express somatostatin receptors.

LUTATHERA 370 MBq is administered intravenously by healthcare professionals in a controlled medical setting.

Common side effects may include fatigue, nausea, vomiting, and a temporary decrease in blood cell counts.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety.

Long-term use should be monitored by a healthcare professional to assess ongoing safety and effectiveness.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.